3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
4
Sarcoma, Endometrial Stromal
1
Recurrence
1
Perivascular Epithelioid Cell Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Endometrial Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Neoplasms, Male
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Adenosarcoma of the uterus
1
Interventions
Temozolomide
6
Radiosurgery
6
pembrolizumab
4
Magnetic Resonance Spectroscopy
4
Bevacizumab
4
Specimen Handling
3
Nivolumab
3
abemaciclib
2
Watchful Waiting
2
Surveys and Questionnaires
2
Receptors, Interleukin-8B
2
Radiation
2
Mental Status and Dementia Tests
2
Memantine
2
Ipilimumab
2
Biopsy
2
vorasidenib
1
sotorasib
1
sapanisertib
1
ribociclib
1
pertuzumab
1
osimertinib
1
lenvatinib
1
fluciclovine F-18
1
entrectinib
1
encorafenib
1
elacestrant
1
brivaracetam
1
binimetinib
1
Valacyclovir
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
elacestrant
×
30 days
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled